Source selection
Selected genetics or biological donor material chosen for the relevant biosynthetic pathway.
Platform
Our development model brings plant-cell culture, analytical characterisation and formulation into a single research pathway.
Cell-based production
Plant cell suspension cultures can provide a controlled route for producing high-value natural products while reducing dependence on conventional whole-plant cultivation.
Leysin is exploring bioreactor-based workflows as a foundation for repeatable research, characterisation and future scale-up.
Specific production yields, scale parameters and commercial readiness are not stated on this website.
How the platform fits together
Selected genetics or biological donor material chosen for the relevant biosynthetic pathway.
Establishment and optimisation of controlled suspension culture and bioreactor conditions.
Analytical work to identify, quantify and understand target compounds and related chemistry.
Development of research formulations designed around stability, precision and future delivery requirements.
Cannabinoid programme
Current planning includes plant-cell work based on selected cannabis genetics. The objective is to investigate reproducible biosynthetic production in controlled culture systems rather than make claims about a finished therapeutic product.
Tryptamine programme
The team’s background includes analytical research on 5-MeO-DMT and prior collaboration concepts around cell-based production and tryptamine biosynthetic pathways. New Leysin programmes remain subject to research, partnership and regulatory development.
Aminoindane programme
Aminoindane-related precursor work is being considered as part of the broader multi-component formulation strategy. Programme details remain exploratory and are intentionally limited at this stage.
Next layer
See how Leysin is approaching formulation and targeted delivery.